A Phase 2b, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of GCS-100 in Patients With Chronic Kidney Disease Caused by Diabetes

Trial Profile

A Phase 2b, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of GCS-100 in Patients With Chronic Kidney Disease Caused by Diabetes

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 May 2017

At a glance

  • Drugs GCS 100 (Primary)
  • Indications Renal failure
  • Focus Therapeutic Use
  • Sponsors La Jolla Pharmaceutical Company
  • Most Recent Events

    • 07 May 2015 After the US FDA indicated that La Jolla Pharmaceutical Company is required to conduct additional chemical characterisation of GCS-100 prior to further clinical development, the company announced its decision to discontinue its galectin-3 inhibitor program. It will continue to treat and follow patients already enrolled in this phase IIb study but will stop enrolling new patients, according to a media release.
    • 07 May 2015 Status changed from recruiting to active, no longer recruiting, according to a La Jolla Pharmaceutical Company media release.
    • 18 Mar 2015 Status changed from not yet recruiting to recruiting, as reported by La Jolla Pharmaceutical Company media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top